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The objective of this study was to measure the vascular endothelial growth 
factor (VEGF) levels in dogs diagnosed with chronic superficial keratitis (CSK). 
The study was performed on 25 German shepherds (14 males and 11 females, aged 
between 3 and 11 years). The VEGF levels were determined in blood serum using 
commercially available enzyme-linked immunosorbent assay (ELISA; Quantikine 
Canine VEGF Immunoassay, R&D Systems). The test group of affected German 
shepherds was subdivided into two subgroups, based on the area of corneal ne-
ovascularisation. The first subgroup (9 patients) comprised dogs with neovascu-
larisation observed in 1 to 2 quadrants of the right and left cornea, while the sec-
ond subgroup (16 patients) comprised dogs with neovascularisation observed in 3 
to 4 quadrants of the right and left cornea. The control group comprised 12 clini-
cally healthy German shepherds (7 males and 5 females, aged between 3 and 9 
years). The results were then statistically analysed by the Mann-Whitney test. The 
study indicated that the median serum VEGF concentration in healthy dogs was 
14.9 pg/mL. The VEGF level observed in sick German shepherds was elevated 
(19.5 pg/mL) as compared to the values found in healthy dogs; however, a statis-
tically significant increase in VEGF concentration, as compared to the values ob-
served in healthy dogs, was only noted in the first subgroup, where the median 
VEGF concentration was 22.0 pg/mL. Elevated serum VEGF concentration was 
observed in German shepherds diagnosed with CSK. A statistically significant in-
crease in VEGF levels was observed in dogs in the first stage of the disease, i.e. 
the early stage of neovascularisation. 
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The cornea is a body part deprived of any blood vessels. Therefore, it can 
be fully transparent, allowing accurate vision. Many pathological processes in 
the cornea of both humans and animals, particularly those of chronic nature, in-
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volve neovascularisation of the cornea (Gilger et al., 2007; Hosseini and Khalili, 
2007; Hosseni and Nejabat, 2007; Balicki and Trbolova, 2010). Neovascularisation 
is also related to immune-mediated corneal diseases, which include chronic su-
perficial keratitis (CSK) (Stanley, 1988; Bedford and Jones, 2001; Balicki, 2005). 
The condition begins with the extension of blood vessels onto the lateral 
limbus of the temporal quadrant of the cornea. Eventually, neovascularisation ex-
tends over a significant part of the cornea, often all of its surface (Balicki, 2005). 
Vasculogenesis is a complex, multistage process regulated by a number of 
stimulants and inhibitors. Vascular endothelial growth factor (VEGF) is one of 
the chief factors stimulating angiogenesis (Ferrara, 2005). It is secreted by a 
number of cell types, including fibroblasts, macrophages, activated platelets and 
neoplastic cells. It is also a 50 times stronger inductor of blood vessel permeabil-
ity than histamine (Ferrara and Davis-Smyth, 1997). Formation of capillaries is 
mainly observed in pathological conditions such as local circulation disorders, 
ischaemia and tissue damage, inflammatory conditions, necrosis and systemic 
diseases such as diabetes, haemangiopathies, chronic leukaemia, rheumatoid ar-
thritis, psoriasis and cancer (Carmeliet and Jain, 2000; Sobczyńska-Rak, 2009). 
Vasculogenesis and VEGF expression are regulated by a number of mechanisms, 
the most important of which seems to be hypoxia. In conditions of lowered oxy-
gen partial pressure, a sudden increase can be observed in the presence of hypoxia 
inducible factor (HIF-1α), which activates the VEGF gene promoter (Rosen, 
2002; Stępień-Wyrobiec et al., 2007). VEGF expression can also be stimulated 
by the cytokines EGF, TGF-β, KGF, PGF2, IGF-1, IL-1 and IL-6. As a strong 
specific mitogen for endothelial cells, VEGF is an angiogenesis mediator most 
often determined in blood serum (Sobczyńska-Rak, 2012). VEGF also signifi-
cantly increases the permeability of endothelium to proteins. It also influences 
the activation of proteolytic enzymes degrading proteins of the extracellular ma-
trix (including metalloproteins), endothelial cell hyperplasia and migration, as 
well as the formation of new blood vessels (Ferrara, 2001). VEGF is believed to 
be responsible for neovascularisation of the cornea which accompanies a number 
of pathological processes of the eye (Zheng et al., 2001; Andreoli and Miller, 
2007). Higher VEGF concentrations have been observed in vascularised corneas 
when compared with corneas free of lesions (Philipp et al., 2000). 
The VEGF receptors -1 (VEGFR1) and -2 (VEGFR2) have been detected 
in pathological vascular endothelium associated with corneal neovascularisation 
in dogs (Binder et al., 2011). The results of this study suggest a role of VEGF re-
ceptors in both physiological and pathological angiogenesis in canine ocular tis-
sue. It has been observed that VEGF, through its receptors VEGFR1 and VEGFR2, 
influences keratitis and corneal vascularisation (Philipp et al., 2000). Establish-
ing the role of VEGF and the significance of its concentration for various disease 
processes is connected to the potential of employing antiangiogenic therapy 
(Hosseini and Nejabat, 2007). VEGF level was measured in the serum in diabetic 
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and nondiabetic cataractous dogs as well as in dogs with intraocular diseases in-
cluding cataract, primary glaucoma, uveitic glaucoma, aphakic/pseudophakic 
glaucoma, retinal detachment, lens luxation and intraocular neoplasia (Abrams et 
al., 2011; Sandberg et al., 2012). 
The objective of this study was to determine the concentration of VEGF in 
the serum of dogs diagnosed with chronic superficial keratitis. 
 
 
Materials and methods 
The study was performed on 25 German shepherds (14 males and 11 fe-
males, aged between 3 and 11 years) diagnosed with CSK. The VEGF levels 
were determined in blood serum using commercially available enzyme-linked 
immunosorbent assay (ELISA, Quantikine Canine VEGF Immunoassay, R&D 
Systems). At each stage, the determination was performed in accordance with the 
manufacturer’s instructions. Blood sera obtained from affected dogs and from 
the control animals were frozen at –75 °C and transported in dry ice to the 
‘DIALAB’ Laboratory of Medical Analyses in Łódź (a laboratory holding the 
E1061R quality control certification issued by the Centre for Quality Certifica-
tion in Laboratory Diagnostics), where the determinations were performed. Test 
result readings were made with the use of a TECAN microplate reader and Ma-
gellan 4.0 software allowing for curvilinear characteristics readings. 
The dogs were divided into two groups. Group 1 comprising affected 
German shepherds was subdivided further into two subgroups based on the ex-
tent of neovascularisation on the corneal surface. The first subgroup (IA, n = 9 
patients) comprised dogs in which the neovascularisation covered between 1 and 
2 quadrants of the right and left cornea, while in the second subgroup (IB, n = 16 
patients) neovascularisation covered between 3 and 4 quadrants of the right and 
left cornea. The control group comprised 12 clinically healthy German shepherds 
(7 males and 5 females, aged between 3 and 9 years). The obtained results were 
statistically analysed. The Kolmogorov-Smirnov test did not indicate normal dis-
tribution of the results, therefore the statistical analysis was based on the Mann-
Whitney test. The correlation between the dogs’ ages and the VEGF levels was 
evaluated using Pearson’s correlation. Probability values of P < 0.05 were con-
sidered significant. 
 
Results 
The VEGF concentrations determined in the different groups are presented 
in Table 1. VEGF concentrations obtained in clinically healthy German shep-
herds and German shepherds diagnosed with CSK are presented in Figs 1–4. As 
compared to concentrations found in healthy dogs, elevated VEGF levels were 
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measured in dogs suffering from CSK. The highest VEGF concentrations (P < 
0.05) were observed in dogs in the early stage of neovascularisation (Figs 5a, b), 
while the lowest values were obtained in dogs in which neovascularisation cov-
ered no less than 3 quadrants of the right or left cornea (Figs 6a, b). A positive 
correlation was found between age and VEGF levels (Pearson’s correlation test; 
rxy = 0.71, P < 0.01) in clinically healthy German shepherds. There was no sig-
nificant correlation between age and VEGF levels (Pearson’s correlation test; 
rxy = 0.04, P > 0.05) in German shepherds diagnosed with CSK. 
Table 1 
Serum vascular endothelial growth factor (VEGF) concentrations in clinically healthy German 
shepherds and in German shepherds diagnosed with chronic superficial keratitis 
VEGF concentration (pg/mL) 
Groups 
Median values Minimum and maximum values 
Control group 14.9 3.6–29.6 
Group I 19.54 9.1–72.5 
Group IA 22.03* 12.0–72.5 
Group IB 17.82 9.1–48.3 
*Statistically significant difference at P < 0.05; Group I: clinically healthy 
dogs; Group IA: patients with neovascularisation covering 1–2 quadrants of 
the left and right cornea; Group IB – patients with neovascularisation cover-
ing 3–4 quadrants of the left and right cornea 
 
 
Discussion 
Angiogenesis and the influence of VEGF on the formation of pathological 
blood vessels have been thoroughly researched and confirmed in a number of 
clinical studies pertaining to disease processes in both humans and animals. At-
tempts have also been made to determine the influence of VEGF on angiogenesis 
in diseases of the eyeball (Philipp et al., 2000; Shakiba et al., 2009). The studies 
of Abrams et al. (2011) and Sandberg et al. (2012) did not find an association be-
tween aqueous humour/plasma VEGF levels and intraocular diseases of dogs. 
VEGF concentration of the aqueous humour was significantly elevated in in-
traocular diseases such as primary glaucoma, uveitic glaucoma, aphakic/ 
pseudophakic glaucoma, retinal detachment, lens luxation and intraocular neo-
plasia, except for primary diabetic cataracts (Sandberg et al., 2012). In this study, 
VEGF concentration in the aqueous humour exceeded that of the blood plasma. 
Sandberg et al. (2012) suggest that aqueous humour VEGF levels in these cases 
are unlikely to be related to circulating VEGF levels and indicate intraocular 
VEGF production. In its physiological state, the cornea is non-vascularised, 
which ensures utmost transparency and facilitates the performance of functions 
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of the organ of sight. The lack of blood vessels in a healthy cornea is due to low 
levels of angiogenic factors and high levels of antiangiogenic factors. Any dis-
turbance of that balance can lead to vessel formation occurring in the cornea 
(Chang et al., 2001). The present study indicated elevated VEGF serum concen-
trations in dogs suffering from CSK. VEGF concentration was statistically sig-
nificantly higher (P < 0.05) in dogs in the early stage of the disease, with a me-
dian value of 22.03 pg/mL (P < 0.05) and a peak concentration of 72.5 pg/mL. In 
comparison, in healthy dogs the maximum median was 29.6 pg/mL. Elevated se-
rum concentrations of an angiogenic factor such as VEGF may indicate its im-
portance in the process of intensive blood vessel formation observed in the early 
stages of CSK. 
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Fig. 1. Vascular endothelial growth factor (VEGF) concentration in healthy dogs (control group) 
0
10
20
30
40
50
60
70
80
0 2 4 6 8 10 12
Age of dogs
VE
G
F 
co
nc
en
tra
tio
n 
 (p
g/
m
l)
 
Fig. 2. Vascular endothelial growth factor (VEGF) concentration in dogs diagnosed with chronic 
superficial keratitis (CSK) 
 
VEGF is a factor stimulating the formation of blood vessels in both 
physiological and pathological processes of the organism. Therefore, serum VEGF 
concentrations in healthy animals can be anywhere between 1 pg/mL and even 
40.1 pg/mL (Clifford et al., 2001; Clifford et al., 2002; Troy et al., 2006; Abrams 
et al., 2011; Aresu et al., 2012). Clifford et al. (2002) conducted a study on dogs 
suffering from tumours and compared the VEGF concentrations of healthy and 
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diseased animals. They observed that in the control group of healthy animals, the 
VEGF levels were between 1 and 18 pg/mL. On the other hand, Aresu et al. (2012) 
reported that the mean growth factor concentration observed in healthy dogs was 
40.1 pg/mL ± 10.4 pg/mL. In the authors’ own research, the serum VEGF con-
centration in healthy dogs was observed to oscillate between 3.6 pg/mL and 
29.6 pg/mL, which with the median of 14.9 pg/mL is similar to values reported 
by other researchers (Clifford et al., 2001; Clifford et al., 2002) and in line with 
natural changeability. The authors created a control group comprising only Ger-
man shepherds and carried on to compare the VEGF levels of diseased German 
shepherds to levels found in healthy dogs of the same breed. 
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Fig. 3. VEGF concentration in dogs diagnosed with CSK – patients with neovascularisation cover-
ing between 1 and 2 quadrants of the left and right cornea (subgroup IA) 
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Fig. 4. VEGF concentration in dogs diagnosed with CSK – patients with neovascularisation cover-
ing between 3 and 4 quadrants of the left and right cornea (subgroup IB) 
 
Abrams et al. (2011) demonstrated that the VEGF level may depend on 
the age and gender of the animal: they observed that in older dogs (10–15 years 
old) the VEGF levels were higher than those measured in young animals. Our 
study also showed a positive correlation (P < 0.01) between age and VEGF lev-
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els in clinically healthy German shepherds, with the VEGF levels being higher in 
older dogs. Chronic superficial keratitis is most often diagnosed in dogs between 
4 and 8 years of age (Balicki, 2005). In the authors’ own research, 84% of the 
dogs diagnosed with CSK were between 4 and 8 years of age and, with one ex-
ception, all dogs were under 10 years old. Statistical analysis revealed no signifi-
cant correlation (P > 0.05) between age and VEGF levels in dogs suffering from 
CSK. It has been observed that the VEGF levels of both the blood plasma and 
the serum were higher in female dogs than in male animals (Abrams et al., 
2011). In contrast, in their study on Alaskan sled dogs, Kemp et al. (2005) found 
higher mean levels in male (21.7 pg/mL) than in female dogs (17.7 pg/mL), and 
the VEGF concentrations of healthy Alaskan sled dogs oscillated between 9 and 
34 pg/mL. Considering this, the present study was conducted on 14 male and 11 
female dogs affected with CSK, while the control group of healthy animals com-
prised 7 male and 5 female animals. 
  
Fig. 5a and 5b. Early stages of chronic superficial keratitis (4-year-old male, subgroup IA, VEGF 
concentration 59.6 pg/mL) 
  
Fig. 6a and 6b. Advanced stages of chronic superficial keratitis (4-year-old male, subgroup IB, 
VEGF concentration 10.2 pg/mL) 
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There is abundant evidence to confirm the participation of VEGF in cor-
neal neovascularisation (Chen et al., 2002; Gan et al., 2004; Zhou et al., 2006). It 
has been demonstrated that VEGF expression is significantly higher in vascular-
ised corneas as compared to healthy ones. The main sources of growth factor in 
the cornea include macrophages, infiltrating leukocytes, the corneal epithelium 
and stromal cells. VEGF overexpression in the cornea promotes several stages of 
angiogenesis, i.e. proteolytic reactions, proliferation, migration and formation of 
vessels from endothelial cells (Shakiba et al., 2009). The pathomechanism of ne-
ovascularisation in cases of CSK remains undetermined. Philipp et al. (2000) ob-
served the presence of receptors characteristic of VEGF in the cornea. The re-
search demonstrated elevated VEGF levels in the blood serum of dogs diagnosed 
with CSK. It is assumed that the most important sources of VEGF in chronic in-
flammatory conditions of the cornea could be macrophages located mainly in the 
stroma of inflamed and vascularised corneas. It is believed that macrophages 
may play a key role in the pathogenesis of pathological neovascularisation of the 
cornea by secreting VEGF directly and by producing other angiogenic factors 
which may also trigger VEGF production by other cells, e.g. epithelial cells and 
keratocytes (Philipp et al., 2000). Williams (1999) demonstrated the presence of 
macrophages in the corneas of dogs suffering from CSK. 
Vasculogenesis of the cornea occurs in dogs in relation to various ocular 
pathological processes, including inflammations or injuries of the cornea, but 
also in connection with immune-mediated diseases such as CSK. Therefore, in 
certain clinical cases there may be a need to monitor the possibility of neovascu-
larisation by determining the concentration of VEGF. In our own research on 
German shepherd dogs diagnosed with CSK, significant VEGF overexpression 
was observed in the early stage of the disease, at the beginning of neovasculari-
sation, which may be related to intensive blood vessel ingrowth into the cornea. 
On the other hand, in dogs in advanced stages of the disease, the VEGF levels 
were elevated but the difference was statistically insignificant and the concentra-
tions were lower than those observed in the early stage. 
The main environmental factor which significantly influences the devel-
opment of CSK is ultraviolet radiation (Chavkin et al., 1994; Gilger et al., 2007). 
It is believed that ultraviolet radiation may influence photochemical changes of 
the cornea, leading to the creation of free radicals and formation of antigens 
(Campbell et al., 1975; Scotto et al., 1988; Stanley, 1988). Therefore, exposure 
to ultraviolet radiation is a factor predisposing dogs to CSK (Bedford and Jones, 
2001). It is believed that both UV radiation itself and the related hypoxia con-
tribute to the activation of genes in macrophages, neutrophils and other cells, in-
cluding those coding for VEGF (Youn et al., 1988; Tacchini et al., 1999). It was 
found that UV radiation induces VEGF expression (Li et al., 2006). Therefore, it 
should be assumed that UV radiation may play a role in the demonstrated eleva-
tion of VEGF levels in dogs suffering from CSK. 
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One of the research interests pertains to the possibility of influencing the 
modulation of angiogenesis with reactive oxygen species (Abid et al., 2001; Co-
lavitti et al., 2002). Research has demonstrated that VEGF stimulates endothelial 
cells to produce peroxynitrite. Peroxynitrite as a second messenger impinges the 
activation of multiple signalling pathways leading to endothelial migration, pro-
liferation, and tube formation in vitro and angiogenesis in vivo (El-Remessy et 
al., 2007). Research conducted by Sreekumar et al. (2006) demonstrated that 
oxidative stress induced by glutathione depletion leads to the induction of 
VEGF-A gene expression and VEGFR-1 and VEGFR-2 receptors in retinal pig-
ment epithelial cells. The study showed that cellular redox status plays an impor-
tant role in VEGF regulation in retinal pigment epithelial cells (Sreekumar et al., 
2006). In dogs suffering from CSK, oxidative stress has been reported. Disorders 
of the antioxidative system and the increased concentrations of protein and lipid 
peroxidation products observed in dogs suffering from CSK indicated the par-
ticipation of reactive oxygen species in the disease process (Balicki, 2005). It can 
be assumed that reactive oxygen species may play a role in the observed eleva-
tion of VEGF concentrations in dogs suffering from CSK, but the actual nature 
of that relationship remains to be determined in the course of future research. 
Based on the results of this study, it can be hypothesised that VEGF plays 
a significant role in corneal neovascularisation in dogs suffering from CSK, 
while another factor is responsible for maintaining the correct morphology of the 
blood vessel network formed during angiogenesis. However, further clinical re-
search is needed to confirm this phenomenon. 
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